Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T83904 Target Info
Target Name NAD-dependent deacetylase sirtuin-2 (SIRT2)
Synonyms SIR2like protein 2; SIR2L2; SIR2L; SIR2-like protein 2; Regulatory protein SIR2 homolog 2; NADdependent protein deacetylase sirtuin2; NAD-dependent protein deacetylase sirtuin-2
Target Type Patented-recorded Target
Gene Name SIRT2
Biochemical Class Carbon-nitrogen hydrolase
UniProt ID
SIR2_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US9737525
Title Small molecule activators of NRF2 pathway
Abstract This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Specifically, the compounds provided herein can act as high affinity reversible bindings for the NRF2 inhibitor, KEAP1. In some cases, NRF2/KEAP1/ARE pathway activation compounds are capable of repressing expression of inflammatory markers and/or reducing levels of TNFa to provide neuroprotective anti-inflammatory effects in the CNS. Such compounds are useful in the treatment of a variety of diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease, inflammation, and cancer.
Applicant(s) The General Hospital Corporation; The Regents of the University of California
Representative Drug(s) D0F6NT Drug Info IC50 = 7000 nM Click to Show More [1]
2 D0Y1WA Drug Info IC50 = 10000 nM [1]
3 D07YHN Drug Info IC50 > 50000000nM [1]
Patent ID US9737525
Title Small molecule activators of NRF2 pathway
Abstract This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Specifically, the compounds provided herein can act as high affinity reversible bindings for the NRF2 inhibitor, KEAP1. In some cases, NRF2/KEAP1/ARE pathway activation compounds are capable of repressing expression of inflammatory markers and/or reducing levels of TNFa to provide neuroprotective anti-inflammatory effects in the CNS. Such compounds are useful in the treatment of a variety of diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease, inflammation, and cancer.
Applicant(s) The General Hospital Corporation; The Regents of the University of California
Representative Drug(s) D0F6NT Drug Info IC50 = 7000 nM Click to Show More [1]
2 D0Y1WA Drug Info IC50 = 10000 nM [1]
3 D07YHN Drug Info IC50 > 50000000nM [1]
Patent ID US9737525
Title Small molecule activators of NRF2 pathway
Abstract This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Specifically, the compounds provided herein can act as high affinity reversible bindings for the NRF2 inhibitor, KEAP1. In some cases, NRF2/KEAP1/ARE pathway activation compounds are capable of repressing expression of inflammatory markers and/or reducing levels of TNFa to provide neuroprotective anti-inflammatory effects in the CNS. Such compounds are useful in the treatment of a variety of diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease, inflammation, and cancer.
Applicant(s) The General Hospital Corporation; The Regents of the University of California
Representative Drug(s) D0F6NT Drug Info IC50 = 7000 nM Click to Show More [1]
2 D0Y1WA Drug Info IC50 = 10000 nM [1]
3 D07YHN Drug Info IC50 > 50000000nM [1]
Patent ID US9365508
Title Aroyl thiourea derivatives
Abstract The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases.
Applicant(s) University Court of the University of St Andrews; University Court of the University of Dundee
Representative Drug(s) D07NKC Drug Info IC50 = 21200 nM Click to Show More [2]
2 D0V2UZ Drug Info IC50 = 32500 nM [2]
3 D00RNS Drug Info IC50 = 39500 nM [2]
Patent ID US9365508
Title Aroyl thiourea derivatives
Abstract The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases.
Applicant(s) University Court of the University of St Andrews; University Court of the University of Dundee
Representative Drug(s) D07NKC Drug Info IC50 = 21200 nM Click to Show More [2]
2 D0V2UZ Drug Info IC50 = 32500 nM [2]
3 D00RNS Drug Info IC50 = 39500 nM [2]
Patent ID US9365508
Title Aroyl thiourea derivatives
Abstract The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases.
Applicant(s) University Court of the University of St Andrews; University Court of the University of Dundee
Representative Drug(s) D07NKC Drug Info IC50 = 21200 nM Click to Show More [2]
2 D0V2UZ Drug Info IC50 = 32500 nM [2]
3 D00RNS Drug Info IC50 = 39500 nM [2]
Patent ID US9359293
Title Methods of treatment using modulators of SIRT2
Abstract The instant application describes novel compounds that modulate (in particular, inhibit) Sirt2 , with structures according to Formulas (1) and (2) provided herein. The invention is also directed to pharmaceutical compositions thereof, methods of treatment (i.e., cancer and neurodegenerative disease) by administration of the modulating compounds, assay methods for finding modulators of Sirt2 , and kits for practicing the assay method.
Applicant(s) CORNELL UNIVERSITY
Representative Drug(s) D0MW0K Drug Info IC50 = 50 nM Click to Show More [3]
2 D0X9SE Drug Info IC50 = 3000 nM [3]
3 D0PL1I Drug Info IC50 = 105000 nM [3]
Patent ID US9359293
Title Methods of treatment using modulators of SIRT2
Abstract The instant application describes novel compounds that modulate (in particular, inhibit) Sirt2 , with structures according to Formulas (1) and (2) provided herein. The invention is also directed to pharmaceutical compositions thereof, methods of treatment (i.e., cancer and neurodegenerative disease) by administration of the modulating compounds, assay methods for finding modulators of Sirt2 , and kits for practicing the assay method.
Applicant(s) CORNELL UNIVERSITY
Representative Drug(s) D0MW0K Drug Info IC50 = 50 nM Click to Show More [3]
2 D0X9SE Drug Info IC50 = 3000 nM [3]
3 D0PL1I Drug Info IC50 = 105000 nM [3]
Patent ID US9359293
Title Methods of treatment using modulators of SIRT2
Abstract The instant application describes novel compounds that modulate (in particular, inhibit) Sirt2 , with structures according to Formulas (1) and (2) provided herein. The invention is also directed to pharmaceutical compositions thereof, methods of treatment (i.e., cancer and neurodegenerative disease) by administration of the modulating compounds, assay methods for finding modulators of Sirt2 , and kits for practicing the assay method.
Applicant(s) CORNELL UNIVERSITY
Representative Drug(s) D0MW0K Drug Info IC50 = 50 nM Click to Show More [3]
2 D0X9SE Drug Info IC50 = 3000 nM [3]
3 D0PL1I Drug Info IC50 = 105000 nM [3]
References  Top
REF 1 Small molecule activators of NRF2 pathway. US9737525.
REF 2 Aroyl thiourea derivatives. US9365508.
REF 3 Methods of treatment using modulators of SIRT2. US9359293.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.